Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.
Soo Heon KwakKyung Ah HanEun Sook KimSung Hee ChoiJong Chul WonJae Myung YuSeungjoon OhHye Jin YooChong Hwa KimKyung-Soo KimSungWan ChunYong Hyun KimSeung Ah ChoDa Hye KimKyong-Soo ParkPublished in: Diabetes, obesity & metabolism (2024)
Enavogliflozin 0.3 mg monotherapy provides long-term glycaemic control in T2DM and is safe and well tolerated during a 52-week treatment period.